CN108524485A - 一种猴睾酮缺乏模型的建立方法 - Google Patents
一种猴睾酮缺乏模型的建立方法 Download PDFInfo
- Publication number
- CN108524485A CN108524485A CN201810157030.1A CN201810157030A CN108524485A CN 108524485 A CN108524485 A CN 108524485A CN 201810157030 A CN201810157030 A CN 201810157030A CN 108524485 A CN108524485 A CN 108524485A
- Authority
- CN
- China
- Prior art keywords
- eds
- testis
- sulfonic acid
- monkey
- testosterone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims abstract description 74
- 229960003604 testosterone Drugs 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 27
- 241000282693 Cercopithecidae Species 0.000 title claims abstract description 19
- 230000002381 testicular Effects 0.000 claims abstract description 27
- 210000001367 artery Anatomy 0.000 claims abstract description 26
- 210000004267 spermatic cord Anatomy 0.000 claims abstract description 20
- 230000017531 blood circulation Effects 0.000 claims abstract description 17
- CAIMYTGDESXCMV-UHFFFAOYSA-N ethane methyl methanesulfonate Chemical compound CC.COS(=O)(=O)C CAIMYTGDESXCMV-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000000903 blocking effect Effects 0.000 claims abstract description 4
- 210000001550 testis Anatomy 0.000 claims description 49
- 230000002146 bilateral effect Effects 0.000 claims description 9
- 210000001015 abdomen Anatomy 0.000 claims description 5
- 210000002640 perineum Anatomy 0.000 claims description 5
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 abstract description 38
- 238000002347 injection Methods 0.000 abstract description 38
- 238000010171 animal model Methods 0.000 abstract description 5
- 150000003515 testosterones Chemical class 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004907 gland Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 244000309464 bull Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 206010058359 Hypogonadism Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 description 2
- 102100027516 Cholesterol side-chain cleavage enzyme, mitochondrial Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 210000002332 leydig cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000011809 primate model Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 241000282562 Macaca radiata Species 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- -1 injection Chemical class 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/106—Primate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种猴睾酮缺乏模型的建立方法,其采用向成年猴***注射二甲基磺酸乙烷结合阻断精索血流的方式。本发明提供了安全、稳定的睾酮缺乏动物模型。
Description
技术领域
本发明属于动物模型领域,具体涉及一种猴睾酮缺乏模型的建立方法。
背景技术
睾酮缺乏综合征(Testosterone deficiency syndrome,TDS)是指在男性一生中的不同时期可能因各种原因导致体内睾酮水平不足而造成其靶器官形态、功能异常,进而引起相应的临床症状,与***、性功能障碍、骨质疏松、抑郁症、心脑血管疾病、糖尿病和代谢综合症等重大疾病的发生发展密切相关,是严重影响男性健康、预期寿命和生活质量的男性生殖内分泌疾病。TDS主要包括迟发性性腺功能减退症(迟发性性腺功能减退(late-onset hypogonadisim,LOH))、先天性性腺功能减退症、***等疾病。随着中国社会老龄化进程,TDS发病率逐年升高,医疗市场需求非常庞大,已成为严重影响我国人民身心健康的重大疾病。目前,临床上治疗TDS主要使用外源性睾酮药物补充疗法,通过口服、注射等途径补充外源性睾酮,虽然有一定疗效,但是由于存在使用不方便和副作用大等明显缺陷,目前仅有很少一部分TDS患者接受该疗法。因此,探索一种治疗TDS的新方法成为我国社会发展中迫切需要解决的关键科技问题。
目前外源性睾酮药物补充疗法是TDS的常用治疗方法。研究证实,患者可从睾酮替代治疗中获益,如***的提高、骨密度的增加、情绪和认知的改善、体质增强等。但是,外源性睾酮药物补充疗法存在明显缺陷:(1)由于患者的睾酮下降水平存在个体差异,造成补充睾酮的剂量难于掌握,剂量过少难于奏效,剂量过大则易于出现副作用和并发症;(2)会造成体内睾酮水平丧失了原有的昼夜节律变化,引起多种并发症;(3)使用不方便,需长期频繁用药;(4)使用外源性睾酮药物会抑制睾丸的生精功能,长期使用会造成少***症或无***症等不育症。由于上述缺陷,目前仅有很少一部分TDS患者在接受外源性睾酮药物治疗。迫切需要探索一种治疗TDS的新方法。体内超95%的睾酮是LCs(Leydig cells,***细胞)合成和分泌的,***细胞数量减少或功能减退被认为是TDS的核心发病机制,这提示细胞移植疗法可能取得较好疗效。而细胞移植疗法的开展有赖于TDS模型的发展,因此TDS模型的研究成为TDS治疗新方法研究领域中的关键问题。
目前TDS模型有两种,一种为老年迟发型性腺功能减退模型,另一种为二甲基磺酸乙烷(ethane-1,2-dimethyl sulphonate,EDS)损伤模型;因老年动物成本高,个体差异大,不易获取等诸多缺点,难以应用。EDS是一种细胞毒性烷化剂,能够选择性杀死大鼠和其他物种的LCs,但是对生***的增殖并不影响。大鼠单次腹腔注射75mg/kg体重的EDS后,可以诱导凋亡而清除大鼠***内成熟的LCs。在注射EDS后6~18小时内逐渐出现LCs核固缩和核碎裂,24小时后大部分LCs出现凋亡,72小时后所有的LCs被清除干净。2~3周左右可以在其***内发现新生的LCs,大约8~10周左右LCs数量恢复到给药前水平。EDS注射14天内血清LH逐渐上升,14~21天内由于新生的LC分泌睾酮而导致血清LH开始下降,21天后血清LH降至注射前水平。EDS注射后的2~8周内,大鼠失去生育功能。其他研究显示,由于EDS注射后导致体内睾酮水平明显下降,包括睾丸、附睾、输精管和精囊在内的生殖器官的重量也明显减少。因此是一种较好的研究TDS细胞移植疗法的理想模型。
然而,尽管大鼠、小鼠等啮齿类动物在科学研究中被广泛使用,但与人类存在较多差异。食蟹猴属灵长类动物,在解剖、生理机能及生化代谢等方面与人类相似,是了解人类生理和病理生理知识的较为理想的实验动物,也是临床转化研究中最重要的模型。为了促进人SLCs治疗TDS的临床转化,评估人SLCs治疗TDS的安全性和有效性,非人灵长类模型的数据是必不可少的,因此建立灵长类动物TDS模型至关重要。但非人灵长类模型十分昂贵,如何保证高效安全地建立动物模型,是人SLCs治疗TDS临床转化十分重要的基础。食蟹猴模型建立的关键在EDS的使用,由于EDS的剂量与肝毒性的发生密切相关,寻找既能诱导非人类灵长类动物稳定的TDS模型又能保证动物的高存活率的EDS最佳剂量和使用方式是非常重要的研究。在食蟹猴TDS模型的建立方面,国内尚未有报道,国外仅见一篇文献报道(Ethane dimethylsulphonate selectively destroys Leydig cells in the adultbonnet monkeys(Macaca radiata))。文献中动物选用的是7-8岁的冠毛猕猴,重6-8千克。作者通过向双侧睾丸内注射5、10、20、50mg的EDS,发现前四天各组睾酮水平出现明显的下降,5mg/testis组的睾酮水平处理后第四天下降到62%,并且在EDS后45天恢复到给药前水平。但是灵长类睾丸中由睾丸纵隔发出许多***小隔,将睾丸实质分成许多锥体形的***,局部注射难以保证EDS的均匀分布及造模效果。另外,EDS具有明显的肝毒性,选择合适的造模剂量、给药方式及评估造模后药物损害也至关重要,但目前尚未见国内外相关报道。因此复制稳定的TDS模型,为研究SLCs治疗TDS有效性、安全性具有重要意义。
发明内容
本发明的目的是针对现有非人灵长类TDS模型的不足,提供一种安全、稳定的睾酮缺乏动物模型,为研究人SLCs治疗TDS有效性、安全性提供良好的基础。
为了实现以上目的,本发明提供了一种猴睾酮缺乏模型的建立方法,其采用向成年猴***注射二甲基磺酸乙烷(EDS)结合阻断精索血流的方式。
根据本发明的方法,注射二甲基磺酸乙烷的量为至少50mg/睾丸。优选地,注射二甲基磺酸乙烷的量为50-200mg/睾丸。优选地,注射二甲基磺酸乙烷的量为50-100mg/睾丸。优选地,注射二甲基磺酸乙烷的量为100-200mg/睾丸。根据本发明的方法,其具体步骤为:将成年食蟹猴麻醉后,消毒其下腹及***部,采用腹股沟内环切口暴露双侧精索,用无损伤钳阻断精索血流20-30分钟;阴囊切口暴露睾丸,将二甲基磺酸乙烷注射入***内。
EDS注射后0、1、2、3、4、5、7、9、11、13、15、20、25、30、35、40、45天上午9点-10点,从上肢静脉采血,每次1-2ml血液,室温静置90分钟,2000g离心15分钟,分离血清,-20℃储存,用于检测睾酮及肝功能。
EDS注射后4、14、28、45天分别进行睾丸穿刺取得睾丸组织,用4%多聚甲醛固定后,在10%、20%、30%蔗糖溶液中梯度脱水至组织沉底,利用OCT包埋,冰冻切片机中行6μm厚的切片,每个时间点5个样品。免疫荧光染色对***细胞特异性蛋白CYP11A1染色。
优选地,将二甲基磺酸乙烷注射入***内的时间为1-5分钟。
根据本发明的方法,所述成年猴的年龄为至少6岁。
本发明的方法选用成年猴(优选食蟹猴),采用***注射EDS结合阻断精索血流的方法,建立了安全、稳定的猴TDS模型。通过连续、长期观测肝脏等指标,证实了本方法能够有效清除成年雄性猴睾丸中LCs,建立了猴TDS模型;此外,本发明的方法降低了EDS导致的肝脏损伤等毒副作用,从而为TDS发病机制研究、药效学研究和其他转化医学临床前研究提供稳定的模型载体。
附图说明
图1是***内注射EDS结合阻断精索血流效果。
图2是食蟹猴睾丸内局部注射EDS和***内注射EDS联合阻断精索血流效果比较。
图3是食蟹猴***注射EDS和***内注射EDS联合阻断精索血流效果比较。
图4是睾丸染色图。
具体实施方式
下面结合具体实施例对本发明的技术方案作进一步的详述,以便于理解。但本发明的保护范围并不限于以下实施例。
实施例1:***内注射EDS结合阻断精索血流,清除***细胞,建立睾酮缺乏模型。
本实验中选用的动物为成年雄性食蟹猴,年龄>6岁,重量8-10kg,共8只成年雄性食蟹猴,随机分为4组,每组2只。
第一组(也称为“溶媒组”)2只食蟹猴双侧***内注射溶媒(DMSO:H2O,1:3,V/V)。EDS溶于溶媒,第二组2只食蟹猴***内注射50mg EDS;第三组2只食蟹猴***内注射100mg的EDS;第四组2只食蟹猴***内注射200mg的EDS。
实验当日,食蟹猴麻醉后,消毒下腹及***部,采用腹股沟内环切口暴露双侧精索,用无损伤钳阻断精索血流20-30分钟;阴囊切口暴露睾丸,相应剂量的EDS缓慢注入***内,注射时间为1-5分钟。
EDS注射后0、1、2、3、4、5、7、9、11、13、15、20、25、30、35、40、45天上午9点-10点,从上肢静脉采血,每次1-2ml血液,室温静置90分钟,2000g离心15分钟,分离血清,-20℃储存,用于检测睾酮及肝功能。
结果参见图1。其中,A:EDS后第4天,溶媒组睾酮水平未受明显影响***内注射50、100、200mg/testis的EDS联合阻断精索血流均能显著降低食蟹猴血清睾酮水平,其中50mg/testis组睾酮水平降至正常水平的30%,100和200mg/testis组睾酮水平低于检测下限0.13ng/ml。50、100、200mg/testis组的睾酮水平在EDS注射后45天恢复至给药前水平。B、C:EDS注射后,溶媒组反映肝脏损伤的指标ALT、AST没有明显变化,处于正常水平;EDS注射后1天,50、100、200mg/testis组ALT、AST升高,且随着剂量的加大不断增高,并于7天内恢复至给药前水平。
EDS注射后4、14、28、45天分别进行睾丸穿刺取得睾丸组织,用4%多聚甲醛固定后,在10%、20%、30%蔗糖溶液中梯度脱水至组织沉底,利用OCT包埋,冰冻切片机中行6μm厚的切片,每个时间点5个样品。免疫荧光染色对***细胞特异性蛋白CYP11A1染色。
图4是睾丸染色图。其中,A:EDS注射后第4天睾丸染色图,图中显示***细胞被全部清除;B:EDS注射后第14天睾丸染色图,图中显示***细胞开始恢复;C:EDS注射后第28天睾丸染色图,图中显示***细胞数量恢复约50%;D:EDS注射后第45天睾丸染色图,图中显示***细胞数量恢复至正常。睾丸切片显示EDS只影响***细胞,但不影响其他细胞。
实施例2:食蟹猴睾丸内局部注射EDS和***内注射EDS联合阻断精索血流效果比较。
另外选用4只成年雄性食蟹猴,年龄>6岁,重量8-10kg,随机分为2组,每组2只。
实验当日,食蟹猴麻醉后,消毒下腹及***部,第一组(也称为“局部组”)2只食蟹猴双侧睾丸局部注射100mg/testis EDS;第二组(也称为“联合组”)2只食蟹猴采用腹股沟内环切口暴露双侧精索,用无损伤钳阻断精索血流20-30分钟;阴囊切口暴露睾丸,将等量EDS缓慢注入***内,注射时间为1-5分钟。
EDS注射后0、1、2、3、4、5、7、9、11、13、15、20、25、30、35、40、45天上午9点-10点,从上肢静脉采血,每次1-2ml血液,室温静置90分钟,2000g离心15分钟,分离血清,-20℃储存,用于检测睾酮及肝功能。
结果参见图2。其中,A:EDS后第4天,睾丸局部注射EDS组(局部组)睾酮水平未受影响,***内注射EDS+阻断精索血流组(联合组)食蟹猴血清睾酮水平低于检测下限0.13ng/ml,并于EDS后45天恢复至给药前水平。B、C:EDS注射后,局部组反映肝脏损伤的指标ALT、AST没有明显变化,处于正常水平;EDS注射后1天,联合组ALT、AST轻度升高,并于4天内恢复至给药前水平。
实施例3:食蟹猴***注射EDS和***内注射EDS联合阻断精索血流效果比较。
另外选择成年雄性食蟹猴4只,年龄>6岁,重量8-10kg,4只成年雄性食蟹猴,随机分为2组,每组2只。
实验当日,食蟹猴麻醉后,消毒下腹及***部,第一组2只食蟹猴双侧***内注射100mg/testis EDS;第二组(也称为“联合组”)采用腹股沟内环切口暴露双侧精索,用无损伤钳阻断精索血流20-30分钟;阴囊切口暴露睾丸,将等量EDS缓慢注入***内,注射时间为1-5分钟。
EDS注射后0、1、2、3、4、5、7、9、11、13、15、20、25、30、35、40、45天上午9点-10点,从上肢静脉采血,每次1-2ml血液,室温静置90分钟,2000g离心15分钟,分离血清,-20℃储存,用于检测睾酮及肝功能。
结果参见图3:A、EDS注射后动脉组食蟹猴睾酮水平呈现下降趋势,并于第3天因肝脏衰竭死亡。EDS注射后第4天,联合组睾酮水平低于检测下限0.13ng/ml,并于EDS后45天恢复至给药前水平。B、C:EDS后第2天,单纯***内注射EDS严重损害食蟹猴肝脏功能,2只食蟹猴均出现明显的肝昏迷症状,并于EDS后第3天死亡。联合组ALT、AST轻度升高,并于4天内恢复至给药前水平。
由以上实验效果可见,本发明的方法通过食蟹猴***内EDS注射联合阻断精索血流,并且连续、长期观测肝脏等指标,证实本方法能够有效清除成年雄性食蟹猴睾丸中LCs,建立了食蟹猴TDS模型;并且降低了EDS导致的肝脏损伤等毒副作用从而为TDS发病机制研究、药效学研究和其他转化医学临床前研究提供稳定的模型载体。
Claims (8)
1.一种猴睾酮缺乏模型的建立方法,其特征在于:采用向成年猴***注射二甲基磺酸乙烷结合阻断精索血流的方式。
2.根据权利要求1所述的方法,其特征在于,注射所述二甲基磺酸乙烷的量为至少50mg/睾丸。
3.根据权利要求1所述的方法,其特征在于,注射所述二甲基磺酸乙烷的量为50-200mg/睾丸。
4.根据权利要求1所述的方法,其特征在于,注射所述二甲基磺酸乙烷的量为50-100mg/睾丸。
5.根据权利要求1所述的方法,其特征在于,注射所述二甲基磺酸乙烷的量为100-200mg/睾丸。
6.根据权利要求1所述的方法,其特征在于,其具体步骤为:将所述成年猴麻醉后,消毒其下腹及***部,采用腹股沟内环切口暴露双侧精索,阻断精索血流;阴囊切口暴露睾丸,将所述二甲基磺酸乙烷注射入***内。
7.根据权利要求1至6任一项所述的方法,其特征在于,将所述二甲基磺酸乙烷注射入***内的时间为1-5分钟。
8.根据权利要求1至6任一项所述的方法,其特征在于,所述成年猴的年龄为至少6岁。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810157030.1A CN108524485A (zh) | 2018-02-24 | 2018-02-24 | 一种猴睾酮缺乏模型的建立方法 |
PCT/CN2018/123563 WO2019161707A1 (zh) | 2018-02-24 | 2018-12-25 | 一种猴睾酮缺乏模型的建立方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810157030.1A CN108524485A (zh) | 2018-02-24 | 2018-02-24 | 一种猴睾酮缺乏模型的建立方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108524485A true CN108524485A (zh) | 2018-09-14 |
Family
ID=63485780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810157030.1A Pending CN108524485A (zh) | 2018-02-24 | 2018-02-24 | 一种猴睾酮缺乏模型的建立方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108524485A (zh) |
WO (1) | WO2019161707A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019161707A1 (zh) * | 2018-02-24 | 2019-08-29 | 中山大学 | 一种猴睾酮缺乏模型的建立方法 |
WO2020228612A1 (zh) * | 2019-05-14 | 2020-11-19 | 中山大学 | 酪氨酸血症i型猴模型及其建立方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010351080B2 (en) * | 2010-04-12 | 2014-08-28 | Tolmar, Inc. | Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same |
GB2482868A (en) * | 2010-08-16 | 2012-02-22 | Franciscus Wilhelmus Henricus Maria Merkus | A testosterone liquid spray formulation for oromucosal administration |
CN105255826B (zh) * | 2015-11-27 | 2019-01-08 | 中山大学 | 人iPS细胞向***细胞的诱导分化方法及其用途 |
CN108524485A (zh) * | 2018-02-24 | 2018-09-14 | 中山大学 | 一种猴睾酮缺乏模型的建立方法 |
-
2018
- 2018-02-24 CN CN201810157030.1A patent/CN108524485A/zh active Pending
- 2018-12-25 WO PCT/CN2018/123563 patent/WO2019161707A1/zh active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019161707A1 (zh) * | 2018-02-24 | 2019-08-29 | 中山大学 | 一种猴睾酮缺乏模型的建立方法 |
WO2020228612A1 (zh) * | 2019-05-14 | 2020-11-19 | 中山大学 | 酪氨酸血症i型猴模型及其建立方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2019161707A1 (zh) | 2019-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cheng et al. | Baicalin improved the spatial learning ability of global ischemia/reperfusion rats by reducing hippocampal apoptosis | |
Liu et al. | Mangiferin Attenuates Myocardial Ischemia‐Reperfusion Injury via MAPK/Nrf‐2/HO‐1/NF‐κB In Vitro and In Vivo | |
Liu et al. | Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice | |
Lian et al. | Effects of an astragalus polysaccharide and rhein combination on apoptosis in rats with chronic renal failure | |
Wang et al. | Traditional Chinese Medicine Ginseng Dingzhi Decoction Ameliorates Myocardial Fibrosis and High Glucose‐Induced Cardiomyocyte Injury by Regulating Intestinal Flora and Mitochondrial Dysfunction | |
Hu et al. | Neuroprotective effects of isosteviol sodium injection on acute focal cerebral ischemia in rats | |
Wang et al. | Network pharmacological analysis and experimental validation of the mechanisms of action of Si-Ni-san against liver fibrosis | |
Sun et al. | Protective effect of extract from Paeonia lactiflora and Astragalus membranaceus against liver injury induced by bacillus Calmette‐Guérin and lipopolysaccharide in mice | |
CN108524485A (zh) | 一种猴睾酮缺乏模型的建立方法 | |
Park et al. | Berberine for appetite suppressant and prevention of obesity | |
Liu et al. | Luteolin protects cardiomyocytes cells against lipopolysaccharide-induced apoptosis and inflammatory damage by modulating Nlrp3 | |
Han et al. | [Retracted] PSMB5 Alleviates Ulcerative Colitis by Inhibiting ROS‐Dependent NLRP3 Inflammasome‐Mediated Pyroptosis | |
AbuKhader et al. | Acute effects of thymoquinone on the pregnant rat and embryo-fetal development | |
Jia et al. | KGF is delivered to inflammatory and induces the epithelial hyperplasia in trinitrobenzene sulfonic acid-induced ulcerative colitis rats | |
WO2020030091A1 (zh) | 用于治疗组织坏死或改善心脏功能的药物 | |
Lin et al. | Shock wave therapy enhances mitochondrial delivery into target cells and protects against acute respiratory distress syndrome | |
Li et al. | RETRACTED: Influence of sodium ferulate on miR-133a and left ventricle remodeling in rats with myocardial infarction | |
CN115261458A (zh) | 17β-HSD7作为非酒精性脂肪性肝病的治疗靶标及其应用 | |
Li et al. | Xiangshao Granules reduce the aggressive behavior and hippocampal injury of premenstrual irritability in rats by regulating JIK/JNK/p38 signal pathway | |
CN104001156B (zh) | 真核肽链释放因子3b片段(eRF3b-36)在治疗肝损伤中的应用 | |
CN113702645A (zh) | Sirt4在心血管疾病治疗中的用途 | |
Akbas | Protective effect of insulin treatment on early renal changes in streptozotocin-induced diabetic rats | |
Hu et al. | Hpyerglycemic effect of a mixture of sea cucumber and cordyceps sinensis in streptozotocin-induced diabetic rat | |
Yuan et al. | [Retracted] Effects of Self‐Made Prescription Compound Rhodiola on the Ultrastructure of Podocytes in Rats with Type 2 Diabetic Nephropathy | |
Zang et al. | [Retracted] Sufentanil Alleviates Sepsis‐Induced Myocardial Injury and Stress Response in Rats through the ERK/GSK‐3β Signaling Axis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180914 |
|
RJ01 | Rejection of invention patent application after publication |